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Purpose: A sleeve lobectomy for lung cancer is a procedure intended both for the maintenance of lung
function and for radical treatment. We investigated the clinico-pathological features and treatment
responses of lung cancer patients who underwent sleeve lobectomy in our department.
Subjects: Among the 984 patients with non-small cell lung cancer who underwent resection in our
department between 1994 and 2007, the subjects were 24 patients in whom a sleeve lobectomy was
performed.
Results: There were 18 male and 6 female patients, with a mean age of 65 years. The histological type was
diagnosed as squamous cell carcinoma in 14 patients, and adenocarcinoma in 10. Patients with either
mucoepidermoid carcinoma (n¼ 1) or carcinoid tumor (n¼ 1) were excluded. The pathological stage was
evaluated as IA, IB, II, IIIA, IIIB, and IV in 4, 1, 8, 8, 2, and 1 patient, respectively. Regarding post-operative
complications, 4 patients required sputum aspiration with a bronchoscope from the 2nd to 7th post-
operative day due to sputum retention. The 5-year survival rate in patients who underwent sleeve
lobectomy was 70.0%. According to the pathological nodal status, the 5-year survival rates of N0, N1, and
N2 were 100.0%, 87.5%, and 41.7%, respectively. The 5-year survival rates in squamous cell carcinoma and
adenocarcinoma were 83.0% and 45.7%, respectively.
Conclusion: Sleeve lobectomy facilitated the maintenance of residual lung function without serious
perioperative complications. This ﬁnding suggests that patients with direct tumor invasion to the
bronchus might be good candidates for a sleeve lobectomy, but not those with extra-nodal invasion.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A sleeve lobectomy is a procedure which preserves the pulmo-
nary function for central tumors of the lung, and the alternative
surgical procedure is a pneumonectomy. The bronchoplasty
procedure, as a parenchyma sparing surgery, was introduced by Sir
Prince Thomas in 1947, and sleeve lobectomy for lung cancer was
performed by Allison in 1952.1,2 Since then, sleeve lobectomy has
been initially introduced in a patient with impaired pulmonary
function.3 The greatest beneﬁt of a sleeve lobectomy is that it can
avoid the pneumonectomy, because pneumonectomy is known to
be associated with signiﬁcant morbidity andmortality, especially in
the case of right pneumonectomy.4,5 The procedure-speciﬁc
complications for bronchoplastic procedures are anastomotic
dehiscence, stenosis and bronchovascular ﬁstula. Previously,
Tedder et al. reported that the incidence of procedure-speciﬁc
complications were 4.8% for bronchial stenosis, 3.0% for: þ81 93 692 4004.
nagiri).
ciates Ltd. Published by Elsevier Ltanastomotic leakage and 2.5% for bronchovascular ﬁstula in
a review of 1125 patients who underwent sleeve lobectomy.6
Bronchoplastic resection is a more technically challenging proce-
dure than a pneumonectomy.
Over the past 2 decades, bronchoplastic techniques, suture
materials, and perioperative management have gradually improved
and have been applied for many patients with locally advanced
lung cancer in the hilar region. Recent studies suggest that a sleeve
lobectomy has now become one of the standard procedures for the
treatment of locoregional cancer of the hilar area, even in patients
with sufﬁcient pulmonary reserve to permit pneumonectomy.7,8
The long-term survival of sleeve lobectomy patients has been
reported to be similar or favorable in comparison to that of pneu-
monectomy patients, with a lower rate of post-operative compli-
cations and better preservation of pulmonary function.8,9 The
surgical indications for a sleeve lobectomy in patients with lymph
node positive disease remain controversial.10 In the present study,
we investigated the clinico-pathological features and treatment
responses of lung cancer patients who underwent this technique in
our department.d. All rights reserved.
Table 1
Characteristics of patients that underwent a sleeve lobectomy or a pneumonectomy.
Sleeve lobectomy Pneumonectomy
Age (mean) 65.1 64.7
Male/female 18/6 61/11
Preoperative lung function
FVC (meanþ SD) 3059þ 734 ml 3092þ 717 ml
% FVC 99.5þ 17.7 97.1þ 17.8
FEV1.0 (meanþ SD) (ml) 2168þ 662 ml 2089þ 514 ml
% FEV1.0 69.9þ 10.0 68.7þ 12.1
Histologic type
Squamous cell carcinoma 14 (58.3) 46 (63.9)
Adenocarcinoma 10 (41.6) 17 (23.6)
Large cell carcinoma 0 7 (9.7)
Adenosquamous carcinoma 0 2 (2.8)
pStage
IA 4 (16.7) 1 (1.4)
IB 1 (4.2) 4 (5.6)
IIA 1 (4.2) 1 (1.4)
IIB 7 (29.2) 12 (16.7)
IIIA 8 (33.3) 34 (47.2)
IIIB 2 (8.3) 16 (22.2)
IV 1 (4.2) 4 (5.6)


























Fig. 2. Comparison of overall survival curves according to the nodal status. According
to the pathological nodal status, the 5-year survival rates of N0, N1 and N2 patients
were 100.0%, 87.5% and 41.7%, respectively. The patients with N0 and N1 disease had
a signiﬁcantly more favorable survival rate than did those with N2 disease (p¼ 0.04).
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The hospital records of 984 consecutive patients who under-
went a resection of non-small cell lung cancer in our department
between 1994 and 2007 were reviewed. Among them, the subjects
included 24 patients in whom a sleeve lobectomy was performed.
During this period, 72 patients underwent pneumonectomy. The
preoperative assessments included chest roentgenography,
computed tomography (CT) of the chest and upper abdomen, and
bone scintigraphy. Clinical N2 status was deﬁned by the presence of
a lymph node with a short diameter of more than 1 cm. MRI
(magnetic resonance imaging) of the brainwas routinely employed.
Bronchoscopy was performed for endobronchial staging and eval-
uating the resection margin of the sleeve lobectomy. The patients’
records including the clinical data, preoperative examination
results, details of the surgical operation, histopathological ﬁndings
and the TNM stages of all patients were also reviewed.80
100
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Fig. 1. Comparison of the overall survival curves for patients undergoing a sleeve
lobectomy and a pneumonectomy. The 5-year survival rates in patients who under-
went a sleeve lobectomy and a pneumonectomy were 70.2% and 33.5% (p¼ 0.01). In all
patients (n¼ 984) who underwent a resection of non-small cell lung cancer in the
same period, the 5-year survival rate was 64.2%.The pulmonary resections were performed by a posterolateral
thoracotomy. The bronchial anastomoses were performed using
interrupted 4-0 braided absorbable sutures. An intraoperative
frozen section of the resection margin was routinely performed to
conﬁrm oncologic completeness. All patients underwent system-
atic hilar and mediastinal lymph node dissection. All resected
specimens including the primary tumor and resected hilar and
mediastinal lymph nodes were examined for tumor histology and
the extent of lymph node metastases. The histopathological ﬁnd-
ings were classiﬁed according to the World Health Organization
criteria, and the UICC TNM staging system was employed.11,12
Bronchoscopy was routinely performed to ensure a completeness
of anastomosis at the end of the procedure. Epidural anesthesiawas
routinely used to reduce post-operative pain and to enable the
patients to clear respiratory secretions through improved coughing
and deeper inspiration.
Follow-up information was obtained from all patients through
ofﬁce visits or telephone interviews with the patient, with a rela-
tive, or with their primary physicians. The patients were evaluated





















Fig. 3. Comparison of the overall survival curves between patients with squamous cell
carcinoma and those with adenocarcinoma. The 5-year survival rates of patients with
squamous cell carcinoma and adenocarcinoma were 83.0% and 45.7%, respectively. The
patients with squamous cell carcinoma showed a better prognosis signiﬁcantly
(p¼ 0.02).
Table 2
Univariate and multivariate analysis for predictors of survival after sleeve lobectomy.
Variable Univariate Multivariate
Hazard ratio 95% Conﬁdence interval p Value Hazard ratio 95% Conﬁdence interval p Value
Age 0.66 0.13–3.33 0.616 Not applicable
Gender (female vs male) 0.72 0.14–3.56 0.689 Not applicable
T factor (T1 vs T2-4) 0.35 0.08–1.54 0.164 Not applicable
N factor (N0, N1 vs N2) 0.24 0.06–0.99 0.049 0.40 0.07–1.52 0.151
Histology (squamous ca. vs adenocarcinoma) 0.18 0.04–0.91 0.038 0.32 0.05–1.21 0.081
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years after surgery and annually thereafter. The mean observation
time was 3.5 years.
The survival curve was calculated by the Kaplan–Meier method
and compared by using the Log-rank test for the univariate analysis.
The prognostic factors were analyzed by a multivariate analysis
using Cox’s proportional hazard model after adjusting for any
potential confounding factors. Categorical variables were compared
by Fisher’s exact test. The differences were considered to be
signiﬁcant if the p valuewas less than 0.05. The Statview V software
program (Abacus Concept, Berkeley, CA) was used for all statistical
analyses.
3. Results
There were 18 male and 6 female patients, and the mean age of
the patients was 65.1 years (range, 43–79 years) (Table 1). The
histological type was diagnosed as squamous cell carcinoma in 14
patients, and adenocarcinoma in 10. Patients with either mucoe-
pidermoid carcinoma (n¼ 1) or carcinoid tumor (n¼ 1) were
excluded. The pathological stage was evaluated as IA, IB, II, IIIA, IIIB,
and IV in 4, 1, 8, 8, 2, and 1 patient, respectively. The patient with
stage IV had pulmonary metastasis to the ipsilateral different lobe.
Concerning the operative procedures, a right sleeve upper lobec-
tomywas performed in 14 patients, a left sleeve upper lobectomy in
2, right middle and a lower sleeve bilobectomy in 3, a left lower
sleeve lobectomy in 3, and a right upper sleeve lobectomy with
carinoplasty in 2. The carinal reconstructions in these cases were
performed with end-to-end anastomosis of trachea and left main
bronchus, and end-to-side anastomosis of right bronchus inter-
medius and left main bronchus.
Regarding the post-operative complications, 4 patients required
sputum aspiration with a bronchoscope from the 2nd to 7th post-
operative day due to sputum retention. One patient had chylo-
thorax and 1 had atrial ﬁbrillation as a post-operative complication,
and these patients were controlled by conservative and medical
management, respectively. The 5-year survival rate in patients whoTable 3
Comparison of mortality morbidity and survival between sleeve lobectomy and pneumo
Author Operative procedure No. of patients Mortality (
Okada et al. Sleeve lobectomy 60 0
Pneumonectomy 60 2
Deslauriers et al. Sleeve lobectomy 184 1.6
Pneumonectomy 1046 5.3
Kim et al. Sleeve lobectomy 49 6.11
Pneumonectomy 49 4.1
Ludwig et al. Sleeve lobectomy 116 4.3
Pneumonectomy 194 4.6
Takda et al. Sleeve lobectomy 62 4.8
Pneumonectomy 110 3.6
Present series Sleeve lobectomy 24 0
Pneumonectomy 72 1.3
a Survival rate in patients with N0 and N1.underwent a sleeve lobectomy was 70.0% (Fig. 1). Among 984
patients, 72 patients underwent total pneumonectomy in the same
period, and the 5-year survival rate was 33.5%. There was no
signiﬁcant difference in the preoperative lung function (forced vital
capacity and forced expiratory volume in 1 s) between a sleeve
lobectomy group and a pneumonectomy group (Table 1).
The reasons for selecting a sleeve lobectomy consisted of direct
tumor invasion in 15 patients and extra-nodal invasion of
a metastatic lymph node in 9. According to the pathological nodal
status, the 5-year survival rates of N0, N1, and N2 were 100.0% and
87.5%, and 41.7%, respectively (Fig. 2). The patients with N0 and N1
disease had a more signiﬁcantly favorable survival than those with
N2 disease (p¼ 0.04). When the prognosis of N2 disease was
compared between a sleeve lobectomy and a pneumonectomy, the
5-year survival rates were 41.7% and 19.8%, respectively. The
5-year survival rates for patients with squamous cell carcinoma
and adenocarcinoma were 83.0% and 45.7%, respectively (Fig. 3).
All of the patients with squamous cell carcinoma underwent
sleeve lobectomy due to direct tumor invasion, whereas the
patients with adenocarcinoma had extra-nodal invasion, except
for 1 patient. The patients with squamous cell carcinoma showed
a better prognosis (p¼ 0.02). Neither suture failure nor stenosis at
the anastomotic site was observed. There were no surgery-related
or hospital deaths in the patients who underwent a sleeve
lobectomy in this study. In a multivariate analysis using variables
such as pathological N factor, and histology as signiﬁcant prog-
nostic factors in univariate analysis, N factor and histology were
not found to be signiﬁcant independent prognostic factors. The
hazard ratio of N0, N1 vs N2 was 0.40 (95% conﬁdence interval
0.07–1.52, p¼ 0.151), and the hazard ratio of squamous cell
carcinoma vs adenocarcinoma was 0.32 (95% conﬁdence interval
0.05–1.21, p¼ 0.081) (Table 2).
4. Discussion
A pneumonectomy has been the operation of choice for patients
with advanced non-small cell lung cancer in the hilar region.nectomy.
%) Morbidity (%) 5-year survival (%) Ref.
Total N0 N1 N2
13 48 70a 21 7
22 28 42a 16
– 52 63 48 8 144
– 31 43 30 21
51 60 88 52 – 10
35 54 75 36 –
38 39 56 38 24 8
26 27 47 30 12
45 54 – – – 26
41 33 – – –
25 70 100 88 42
– 34 40 54 20
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a pneumonectomy for patients with an impaired pulmonary
function in order to preserve the pulmonary parenchyma. In these
past 2 decades, bronchoplastic techniques using absorbable suture
materials, and perioperative managements, such as isolated
unilateral lung ventilation and respiratory physical therapy, have
improved and have been used in many patients with central
tumors.13,14 A successful outcome of bronchoplasty depends on
a reliable suture technique with maintenance of adequate blood
ﬂow and minimal tension at the anastomotic site. An interruption
of the bronchus and denervation of the pulmonary branch of the
vagus nerve are known to decrease ciliary movement of the bron-
chial mucosa, and reduce the cough reﬂex, thus causing sputum
retention.15 The procedure-related complications consisted of
pneumonia, atelectasis, stenosis at the anastomotic site, bronchial
ﬁstula and broncho-pulmonary arterial ﬁstula. The complications
of bronchial anastomosis were reported to occur in from 3 to 6% of
patients with a sleeve lobecttomy.16,17 Ludwig et al. reported the
mortality rate within 30 days after bronchoplasty for lung cancer to
be 4.3%, which was similar to that after a total pneumonectomy
(4.6%).8 Several studies have reported that sleeve lobectomy could
be performed with a lower operative mortality and better quality of
life than that of pneumonectomy (Table 3).16–18 Furthermore,
a sleeve lobectomy tends to provide a better prognosis than
a pneumonectomy (Table 3). In this study, there were no surgery-
related or hospital deaths among the patients. Neither anastomotic
leak nor stenosis at the anastomotic site was observed. Four
patients required sputum aspiration with a bronchoscope from the
2nd to 7th post-operative day due to sputum retention.
Several studies have reported that themost frequent location for
a sleeve resection was the right upper lobe.8,16,17 In this study, the
oriﬁce of right upper lobe was also the most common site of tumor
invasion. It might be anatomical reason for tendency to decide right
sleeve lobectomy, because there is an intermediate bronchus
between the right upper lobe and the middle and lower lobes. Due
to the intermediate bronchus, a cancer-free surgical margin of
a right-sided sleeve resection is more feasible to perform than that
of the left side. This is also important to avoid a right pneumo-
nectomy, because right pneumonectomy is reported to cause
signiﬁcantly higher morbidity and mortality than that of left
pneumonectomy.4,5,19 In a comparison of the surgical outcomes, the
pneumonectomy showed a signiﬁcantly more unfavorable prog-
nosis than that of the sleeve lobectomy in this study. However, the
background of the 2 groups was signiﬁcantly different in their
pathological stage, and patients with more advanced disease ten-
ded to undergo pneumonectomy in this study. Therefore, it is
difﬁcult to compare directly the outcome of these operative
procedures in this retrospective study (Table 1).
A sleeve lobectomy has been indicated in patients who cannot
withstand pneumonectomy from the viewpoint of their pulmonary
function; however, recent experience has shown that the tech-
nique may also be performed not only for sparing lung paren-
chyma, but also to achieve a curative resection in patients without
cardiopulmonary impairment. Although no randomized trials, only
retrospective analysis of the data, are available to compare these
two procedures, recent investigations support the concept that
a sleeve lobectomy is intended to achieve both curative treatment
and the preservation of the lung function. When the main tumor
has directly invaded the 2nd carina of the bronchus without lymph
node metastasis, and a simple lobectomy is expected to result in an
incomplete resection, a sleeve lobectomy is considered to be a good
indication. Lymph node metastasis is a signiﬁcantly unfavorable
prognostic factor in relation to survival.7,16,17 In particular, locore-
gional recurrence has been associated with lymph node metas-
tasis.10 It is considered that a sleeve lobectomy should be carefullyapplied to patients with nodal involvement limited to the hilar
lymph nodes. However, Burfeind et al. reported that a broncho-
plastic resection for N2 disease could be performed with low
morbidity and mortality rates, even after induction chemo-
radiotherapy.20 In this study, patients with N2 disease had
a signiﬁcantly poor prognosis in comparison to patients with N0
and N1 disease (Fig. 2). Therefore, patients with N0 and N1 disease
were suggested to be better candidates for a sleeve lobectomy in
this study. However, in a comparison of the prognosis of N2
disease, the 5-year survival rates were better for a sleeve lobec-
tomy (41.7%) than for a pneumonectomy (19.8%). This ﬁnding
suggested that a sleeve lobectomy still provides some beneﬁts for
selected patients with N2 disease. Moreover the prognosis of
patients with squamous cell carcinoma was signiﬁcantly better
than that of those with adenocarcinoma (Fig. 3). The signiﬁcant
difference of the prognosis is to be due to the different reasons for
choice of the sleeve lobectomy. The indication for a sleeve lobec-
tomy was the presence of direct tumor invasion in all patients with
squamous cell carcinoma. On the other hand, the invasion of
a metastatic lymph node was the reason to choose a sleeve
lobectomy in patients with adenocarcinoma, with the exception of
1 case. Because the mediastinal nodal status is an important
prognosis factor, cervical mediastinoscpy might therefore play an
important role in planning treatment strategy according to pre-
surgical staging of mediastinal lymph nodes.21 Positron emission
tomography with18 F-ﬂuoro-2-deoxy-D-glucose and computed
tomography (PET/CT) has been also reported to provide high
speciﬁcity and accuracy in the intrathoracic nodal staging of NSCLC
patients.22
Burfeind et al. reported that induction chemoradiotherapy could
be useful for performing bronchoplastic procedure.20 Induction
therapy has some advantages such as a reduction in tumor size,
which will increase the possibility of a complete resection. In this
study, the 2 patients received bronchial arterial infusion using
CDDP as an induction therapy, and thereafter underwent a right
upper sleeve lobectomy with carinoplasty without any severe
complication.23 Bronchial arterial infusion is considered to be an
effective and feasible modality for local advancer NSCLC. Recently
adjuvant chemotherapy has become a standard care for patients
with NSCLC.24,25 Therefore, we performed adjuvant chemotherapy
for 6 patients after 2002. However, there has so far been no
investigation conducted regarding the clinical signiﬁcance of
adjuvant chemotherapy after sleeve lobectomy.
In conclusion, a sleeve lobectomy facilitated the maintenance of
post-operative residual lung functionwithout serious perioperative
complications, and yielded an acceptable long-term survival, thus
suggesting its usefulness as a radical treatment. The ﬁndings sug-
gested that patients with direct tumor invasion to bronchus but not
extra-nodal invasion might therefore be good candidates for
a sleeve lobectomy. A positive nodal status was an unfavorable
prognostic factor, and especially patients with an N2 positive
lymph node status had a poorer prognosis than those with N0 and
N1 disease.
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